Skip to main content

Annexon Biosciences, Inc. (ANNX)

NASDAQ: ANNX · IEX Real-Time Price · USD
21.05
+0.10 (0.47%)
After-hours:Sep 24, 2021 4:04 PM EDT
20.95
-0.88 (-4.03%)
At close: Sep 24, 4:00 PM
Market Cap817.44M
Revenue (ttm)n/a
Net Income (ttm)-102.50M
Shares Out38.33M
EPS (ttm)-2.86
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume118,957
Open21.51
Previous Close21.83
Day's Range20.74 - 21.71
52-Week Range15.52 - 38.01
Betan/a
AnalystsStrong Buy
Price Target37.00 (+76.6%)
Est. Earnings DateNov 15, 2021

About ANNX

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune and neurodegenerative diseases. It focuses on the treatment of body, brain, and eye disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, which has completed Phase 1b clinical trials to treat patients with guillain- barré syndrome; an...

IndustryBiotechnology
IPO DateJul 24, 2020
Employees57
Stock ExchangeNASDAQ
Ticker SymbolANNX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for ANNX stock is "Strong Buy." The 12-month stock price forecast is 37.00, which is an increase of 76.61% from the latest price.

Price Target
$37.00
(76.61% upside)
Analyst Consensus: Strong Buy

News

Annexon Biosciences to Participate in 2021 Cantor Virtual Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...

2 days ago - GlobeNewsWire

Annexon Biosciences to Highlight Neurodegeneration Franchise in Upcoming Virtual C1q Series R&D Event

CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...

5 days ago - GlobeNewsWire

Annexon Biosciences Reports Second Quarter 2021 Financial Results and Provides Mid-Year Business Update

– Recently expanded Autoimmune franchise with advancement of third clinical candidate, ANX009, and strategically expanded into additional autoantibody-driven diseases –

1 month ago - GlobeNewsWire

Annexon Broadens Autoimmune Franchise with Advancement of Third Anti-C1q Product Candidate and Strategic Expansion in...

Advancing subcutaneous ANX009 candidate into Phase 1b program in Lupus Nephritis

2 months ago - GlobeNewsWire

Annexon to Present at the Raymond James Human Health Innovation Conference

SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- Today,  Annexon, Inc.  (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for ...

3 months ago - GlobeNewsWire

Moving Average Crossover Alert: Annexon (ANNX)

Annexon (ANNX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

4 months ago - Zacks Investment Research

Annexon Biosciences Provides Business Update and Reports First Quarter 2021 Financial Results

– ANX005 Huntington's Disease Phase 2 trial fully enrolled with data anticipated 2H 2021 –

4 months ago - GlobeNewsWire

Annexon to Present at the BofA Securities 2021 Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Today Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for pati...

4 months ago - GlobeNewsWire

Annexon Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results with Recent Business Highlights

SOUTH SAN FRANCISCO, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Today Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for pa...

6 months ago - GlobeNewsWire

Annexon Shares Gain After Patient Dosing Starts In Mid-Stage Study For Vision Loss Disorder Therapy

Annexon Inc (NASDAQ: ANNX) has commenced patient dosing in its Phase 2 ARCHER study evaluating ANX007 to treat Geographic Atrophy (GA). GA, also known as atrophic age-related macular degeneration (AMD) ...

6 months ago - Benzinga

Annexon Advances Classical Complement Platform with Initiation of Global Phase 2 ARCHER Trial in Patients with Geogra...

SOUTH SAN FRANCISCO, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Today, Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing novel therapies for patients with c...

6 months ago - GlobeNewsWire

Annexon Welcomes William H. Carson, M.D.

Thomas G. Wiggans appointed Chairman Thomas G. Wiggans appointed Chairman

7 months ago - GlobeNewsWire

BMEZ: Healthcare Exposure With A ~4% Yield And Growth Potential

BMEZ delivered solid results throughout 2020, helped by the healthcare sector overall. This fund doesn't just invest in your typical healthcare companies though and tilts towards smaller and private inv...

7 months ago - Seeking Alpha

Annexon Highlights Recent Achievements and Outlines Expected Key Milestones in 2021 for Its Broad Portfolio of Comple...

SOUTH SAN FRANCISCO, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for patients ...

8 months ago - GlobeNewsWire

Annexon to Present at the J.P. Morgan 39th Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for patients ...

8 months ago - GlobeNewsWire